Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Olivero Website

Ofelia A. Olivero, Ph.D.

Selected Publications

1)  Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC.
Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.
J. Natl. Cancer Inst. 89: 1602-8, 1997.
2)  Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC.
Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero.
AIDS. 13: 919-25, 1999.
3)  Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL, Poirier MC.
Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells.
Mutagenesis. 20: 139-46, 2005.
4)  Olivero OA.
Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors.
Environ. Mol. Mutagen. 48: 215-23, 2007.
5)  Olivero OA, Torres LR, Gorjifard S, Momot D, Marrogi E, Divi RL, Liu Y, Woodward RA, Sowers MJ, Poirier MC.
Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age.
J. Infect. Dis. 208: 244-8, 2013.
6)  Olivero OA, Ongele MO, Braun HM, Marrogi A, Divi K, Mitchell JB, Poirier MC.
Selective protection of zidovudine-induced DNA-damage by the antioxidants WR-1065 and tempol.
Environ. Mol. Mutagen. 2014.
7)  Fernandez-Madrid F, Maroun M, Olivero O, Grossman L, Binder W, Abrams J, Chen W, Tang N, Zhang X, Dong J, Stark A, Burke M, Nathanson S, Zarbo R, Chitale D, Long M, Zeballos-Chavez R, Haak P, Koo S, Peebles C.
Autoantibodies in breast cancer are reminiscent of the autoantibody response in the autoimmune diseases.
Clin Cncer Res. 2013.
In Press. [Journal]
8)  Olivero OA.
Centrosomal amplification and related abnormalities induced by nucleoside analogs. In: Centrosomes.
Humana Press; 2012. In Press. [Book Chapter]
9)  John K, Pratt MM, Beland FA, Churchwell MI, McMullen G, Olivero OA, Pogribny I, Poirier MC.
Benzo[a]pyrene (BP) DNA adduct formation in DNA repair deficient p53 haploinsufficient [Xpa(-/-)p53(+/-)] and wild type mice fed BP and BP plus chlorophyllin for 28 days.
Carcinogenesis. 2012.
10)  Pratt MM, King LC, Adams LD, John K, Sirajuddin P, Olivero OA, Manchester DK, Sram RJ, DeMarini DM, Poirier MC.
Assessment of multiple types of DNA damage in human placentas from smoking and nonsmoking women in the Czech Republic.
Environ. Mol. Mutagen. 52: 58-68, 2011.
11)  Olivero OA, Larramendy M, Soloneski S, Menck CF, Matta J, Folle GA, Zamorano-Ponce E, Spivak G.
Impact of EMS outreach: successful developments in Latin America.
Environ. Mol. Mutagen. 51: 763-73, 2010.
12)  Olivero OA, Vazquez IL, Cooch CC, Ming J, Keller E, Yu M, Borojerdi JP, Braun HM, McKee E, Poirier MC.
Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells.
Toxicol. Sci. 115: 109-17, 2010.
13)  Dutra A, Pak E, Wincovitch S, John K, Poirier MC, Olivero OA.
Nuclear bud formation: a novel manifestation of Zidovudine genotoxicity.
Cytogenet. Genome Res. 128: 105-10, 2010.
14)  Poirier MC, Olivero OA, Hardy AW, Franchini G, Borojerdi JP, Walker VE, Walker DM, Shearer GM.
Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.
AIDS Res Ther. 6: 24, 2009.
15)  Borojerdi JP, Ming J, Cooch C, Ward Y, Semino-Mora C, Yu M, Braun HM, Taylor BJ, Poirier MC, Olivero OA.
Centrosomal amplification and aneuploidy induced by the antiretroviral drug AZT in hamster and human cells.
Mutat. Res. 665: 67-74, 2009.
16)  Yu M, Ward Y, Poirier MC, Olivero OA.
Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosine.
Environ. Mol. Mutagen. 50: 718-24, 2009.
17)  Sackett DL, Olivero O.
Centrosome structure and function under normal and pathological conditions.
Environ. Mol. Mutagen. 50: 591-2, 2009.
18)  Schild-Hay LJ, Leil TA, Divi RL, Olivero OA, Weston A, Poirier MC.
Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells.
Cancer Res. 69: 1150-5, 2009.
19)  Walker DM, Kajon AE, Torres SM, Carter MM, McCash CL, Swenberg JA, Upton PB, Hardy AW, Olivero OA, Shearer GM, Poirier MC, Walker VE.
WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.
Environ. Mol. Mutagen. 2009.
20)  Olivero OA, Ming JM, Das S, Vazquez IL, Richardson DL, Weston A, Poirier MC.
Human inter-individual variability in metabolism and genotoxic response to zidovudine.
Toxicol. Appl. Pharmacol. 228: 158-64, 2008.
21)  van Gijssel HE, Leil TA, Weinberg WC, Divi RL, Olivero OA, Poirier MC.
Cisplatin-DNA damage in p21WAF1/Cip1 deficient mouse keratinocytes exposed to cisplatin.
Mutagenesis. 22: 49-54, 2007.
22)  Escobar PA, Olivero OA, Wade NA, Abrams EJ, Nesel CJ, Ness RB, Day RD, Day BW, Meng Q, O'Neill JP, Walker DM, Poirier MC, Walker VE, Bigbee WL.
Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC.
Environ. Mol. Mutagen. 48: 330-43, 2007.
23)  Torres SM, Walker DM, Carter MM, Cook DL, McCash CL, Cordova EM, Olivero OA, Poirier MC, Walker VE.
Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations.
Environ. Mol. Mutagen. 48: 224-38, 2007.
24)  Meng Q, Olivero OA, Fasco MJ, Bellisario R, Kaminsky L, Pass KA, Wade NA, Abrams EJ, Nesel CJ, Ness RB, Bigbee WL, O'Neill JP, Walker DM, Poirier MC, Walker VE.
Plasma and cellular markers of 3'-azido-3'-dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs.
Environ. Mol. Mutagen. 48: 307-21, 2007.
25)  Pratt MM, Sirajuddin P, Poirier MC, Schiffman M, Glass AG, Scott DR, Rush BB, Olivero OA, Castle PE.
Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study.
Mutat. Res. 624: 114-23, 2007.
26)  Olivero OA.
Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy.
Mutat. Res. 658: 184-90, 2007.
27)  Divi RL, Haverkos KJ, Humsi JA, Shockley ME, Thamire C, Nagashima K, Olivero OA, Poirier MC.
Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine.
Environ. Mol. Mutagen. 48: 179-89, 2006.
28)  Gwinn MR, Keshava C, Olivero OA, Humsi JA, Poirier MC, Weston A.
Transcriptional signatures of normal human mammary epithelial cells in response to benzo[a]pyrene exposure: a comparison of three microarray platforms.
OMICS. 9: 334-50, 2005.
29)  Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, St Claire MC, Nagashima K, Harbaugh SW, Harbaugh JW, Olivero OA, Divi RL, Albert PS, Poirier MC.
Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine.
AIDS Res. Hum. Retroviruses. 20: 91-100, 2004.
30)  Poirier MC, Olivero OA, Walker DM, Walker VE.
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
Toxicol. Appl. Pharmacol. 199: 151-61, 2004.
31)  Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA.
Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.
J. Acquir. Immune Defic. Syndr. 33: 175-83, 2003.
32)  van Gijssel HE, Divi RL, Olivero OA, Roth MJ, Wang GQ, Dawsey SM, Albert PS, Qiao YL, Taylor PR, Dong ZW, Schrager JA, Kleiner DE, Poirier MC.
Semiquantitation of polycyclic aromatic hydrocarbon-DNA adducts in human esophagus by immunohistochemistry and the automated cellular imaging system.
Cancer Epidemiol. Biomarkers Prev. 11: 1622-9, 2002.
33)  Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC.
Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys.
J. Acquir. Immune Defic. Syndr. 29: 323-9, 2002.
34)  Tejera AM, Alonso DF, Gomez DE, Olivero OA.
Chronic in vitro exposure to 3'-azido-2', 3'-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells.
Breast Cancer Res. Treat. 65: 93-9, 2001.
35)  Olivero OA, Reddy MK, Pietras SM, Poirier MC.
Plasma drug levels compared with DNA incorporation of 3'-azido-3'-deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys.
Exp. Biol. Med. (Maywood). 226: 446-9, 2001.
36)  Diwan BA, Olivero OA, Poirier MC.
Absence of structural or functional alterations in male and female reproductive organs of F1 and F2 generations derived from female mice exposed to 3'-azido-3'-deoxythymidine during pregnancy.
Toxicol. Lett. 115: 9-15, 2000.
37)  Roth MJ, Dawsey SM, Wang G, Tangrea JA, Zhou B, Ratnasinghe D, Woodson KG, Olivero OA, Poirier MC, Frye BL, Taylor PR, Weston A.
Association between GSTM1*0 and squamous dysplasia of the esophagus in the high risk region of Linxian, China.
Cancer Lett. 156: 73-81, 2000.
38)  Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Baker R, Stek AM, Khoury MM, Poirier MC.
Incorporation of zidovudine into cord blood DNA of infants and peripheral blood DNA of their HIV-1-positive mothers.
Ann. N. Y. Acad. Sci. 918: 262-8, 2000.
39)  Bialkowska A, Bialkowski K, Gerschenson M, Diwan BA, Jones AB, Olivero OA, Poirier MC, Anderson LM, Kasprzak KS, Sipowicz MA.
Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'-deoxythymidine (AZT).
Carcinogenesis. 21: 1059-62, 2000.
40)  Slikker W, Olivero OA, Patterson TA, Poirier MC.
Potential toxicities of HIV therapeutics in the developing infant.
Teratology. 61: 397-8, 2000.
41)  Meng Q, Su T, Olivero OA, Poirier MC, Shi X, Ding X, Walker VE.
Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymidine.
Toxicol. Sci. 54: 322-9, 2000.
42)  Meng Q, Walker DM, Olivero OA, Shi X, Antiochos BB, Poirier MC, Walker VE.
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells.
Proc. Natl. Acad. Sci. U.S.A. 97: 12667-71, 2000.
43)  Olivero OA, Parikka R, Poirier MC, Vähäkangas K.
3'-azido-3'-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT.
Mutat. Res. 428: 41-7, 1999.
44)  Sussman HE, Olivero OA, Meng Q, Pietras SM, Poirier MC, O'Neill JP, Finette BA, Bauer MJ, Walker VE.
Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT.
Mutat. Res. 429: 249-59, 1999.
45)  Poirier MC, Patterson TA, Slikker W, Olivero OA.
Incorporation of 3'-azido-3'-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose.
J. Acquir. Immune Defic. Syndr. 22: 477-83, 1999.
46)  Diwan BA, Riggs CW, Logsdon D, Haines DC, Olivero OA, Rice JM, Yuspa SH, Poirier MC, Anderson LM.
Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice.
Toxicol. Appl. Pharmacol. 161: 82-99, 1999.
47)  Olivero OA, Gomez DE.
Correspondence re: S. M. Melana et al., Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin. Cancer Res., 4: 693-696, 1998.
Clin. Cancer Res. 4: 2569-70, 1998.
48)  Gomez DE, Tejera AM, Olivero OA.
Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment.
Biochem. Biophys. Res. Commun. 246: 107-10, 1998.
49)  Zhang Z, Diwan BA, Anderson LM, Logsdon D, Olivero OA, Haines DC, Rice JM, Yuspa SH, Poirier MC.
Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3'-azido-2',3'-dideoxythymidine.
Mol. Carcinog. 23: 45-51, 1998.
50)  Giurgiovich AJ, Diwan BA, Olivero OA, Anderson LM, Rice JM, Poirier MC.
Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure.
Carcinogenesis. 18: 93-6, 1997.
51)  Agarwal RP, Olivero OA.
Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxythymidine.
Mutat. Res. 390: 223-31, 1997.
52)  Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, Poirier MC.
Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA.
Mutat. Res. 391: 79-86, 1997.
53)  Giurgiovich AJ, Anderson LM, Jones AB, Dove LF, Moskal TJ, Rice JM, Olivero OA, Poirier MC.
Transplacental cisplatin exposure induces persistent fetal mitochondrial and genomic DNA damage in patas monkeys.
Reprod. Toxicol. 11: 95-100, 1997.
54)  Olivero OA, Semino C, Kassim A, Lopez-Larraza DM, Poirier MC.
Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells.
Mutat. Res. 346: 221-30, 1995.
55)  Gomez D, Kassim A, Olivero O.
Preferential incorporation of 3'-azido-2',3'-dideoxythymidine (azt) in telomeric sequences of cho cells.
Int. J. Oncol. 7: 1057-60, 1995.
56)  Olivero OA, Kassim A.
Purification of mitochondrial DNA using Qiagen columns.. Qiagen Bulletin.
1994. Report No. 1. [Technical Report]
57)  Olivero O, Beland F, Poirier M.
Immumofluorescent localization and quantitation of 3'-azido-2',3'-dideoxythymidine(AZT) incorporation into chromosomal DNA of human, hamster, and mouse cell lines.
Internation Journal of Oncology. 4: 49-54, 1994.
58)  Olivero OA, Beland FA, Fullerton NF, Poirier MC.
Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3'-azido-2',3'-dideoxythymidine.
Cancer Res. 54: 6235-42, 1994.
59)  Olivero OA, Poirier MC.
Preferential incorporation of 3'-azido-2',3'-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells.
Mol. Carcinog. 8: 81-8, 1993.
60)  Olivero OA, Huitfeldt H, Poirier MC.
Chromosome site-specific immunohistochemical detection of DNA adducts in N-acetoxy-2-acetylaminofluorene--exposed Chinese hamster ovary cells.
Mol. Carcinog. 3: 37-43, 1990.
61)  Olivero OA, Semino C, Poirier MC.
Localization of DNA adducts induced by N-acetoxy-N-2-acetylaminofluorene in Chinese hamster ovary cells using electron microscopy and colloidal gold.
Genes Chromosomes Cancer. 2: 130-6, 1990.
62)  Bianchi N, LopezCamelo J, Olivero O, Lopretto E.
An equation to determine the index of karyological conservatism among phylogenetically related species.
Caryologia. 41:(1): 9-15, 1988.
63)  Olivero O, LopezCamelo J, Lopretto E, Bianchi N.
A computer system to detect homologies through chromosome art comparisons.
Caryologia. 40 (4): 275-286, 1987.
64)  Dulout FN, Pastori MC, Olivero OA, González Cid M, Loria D, Matos E, Sobel N, de Bujan EC, Albiano N.
Sister-chromatid exchanges and chromosomal aberrations in a population exposed to pesticides.
Mutat. Res. 143: 237-44, 1985.
65)  Dulout FN, Olivero OA.
Anaphase-telophase analysis of chromosomal damage induced by chemicals.
Environmental mutagenesis. 6: 299-310, 1984.
66)  Dulout FN, Pastori MC, Olivero OA.
Malathion-induced chromosomal aberrations in bone-marrow cells of mice: dose-response relationships.
Mutat. Res. 122: 163-7, 1983.
67)  Dulout FN, Olivero OA, von Guradze H, Pastori MC.
Cytogenetic effect of malathion assessed by the micronucleus test.
Mutat. Res. 105: 413-6, 1982.
68)  Dulout F, Pastori M, Olivero O, vonGuradze H.
Los ensayos citogeneticos in vivo en estudios de mutagenesis quimica.
Actas del V Congreso Latinoamericano de Genetica. 209-225, 1982.
69)  Dulout FN, Olivero OA, Pastori MC.
The mutagenic effect of thiram analysed by the micronucleus test and the anaphase-telophase test.
Mutat. Res. 105: 409-12, 1982.
70)  Dulout FN, Larramendy ML, Olivero OA.
Effect of caffeine on the frequency of chromosome aberrations induced in vivo by triethylenemelamine (TEM) and adriamycin (ADR) in mice.
Mutat. Res. 82: 295-304, 1981.
71)  Dulout FN, Larramendy ML, Olivero OA.
Enhancement by caffeine of the frequency of anaphase-telophase chromatin bridges induced by triethylenemelamine (TEM).
Experientia. 36: 346-7, 1980.
72)  Larramendy ML, Dulout FN, Bianchi NO, Olivero OA.
In vivo dose-response relationship in bone-marrow cells of mice treated with adriamycin.
Mutat. Res. 79: 133-40, 1980.
73)  Dulot F, Larramendy M, Olivero O.
Mecanismos Robertsonianos: evidencias experimentales.
Actas del IV Congreso Latinoamericano X Argentino de Genetica. 2: 261-266, 1980.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/13/2014.